Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAlliance Pharma Share News (APH)

Share Price Information for Alliance Pharma (APH)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 32.85
Bid: 32.85
Ask: 33.10
Change: -0.65 (-1.94%)
Spread: 0.25 (0.761%)
Open: 32.65
High: 33.20
Low: 32.50
Prev. Close: 33.50
APH Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Applied Graphene launches strategic review

Wed, 23rd Nov 2022 11:14

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

----------

AIM - WINNERS

----------

Europa Metals Ltd, up 42% at 3.98 pence, 12-month range 2.5p-5.3p. The lead, zinc and silver mine developer enters into an option agreement with Denarius Metals Corp, granting Denarius the right to acquire up to 80% of its wholly-owned Spanish subsidiary, Europa Metals Iberia. The subsidiary holds the Toral project in northwest Spain. Should shareholders approve the deal, Europa would secure an initial USD4.0 million for the Toral project, with a potential future cash payment of USD2.0 million. The first amount would give Denarius a 51% stake and the second an additional 29%. Europa Metals also conditionally raises GBP580,000 via subscription of 12.9 million new shares at issue price of 4.5p, a 61% premium to the closing price of 2.8p on Tuesday.

----------

Zanaga Iron Ore Co Ltd, up 23% at 4.1p, 12-month range 1.7p-5.2p. The part owner of the Zanaga iron ore project in the Republic of Congo reaches an agreement to buy Glencore Projects' controlling shareholding in the project. This would be enacted via the purchase of Glencore Projects' 50% plus one share interest in Jumelles - an entity which indirectly holds the benefit of the ZIO project's mining license - in exchange for the issue of 286.3 million new shares to Glencore Projects. This would represent a shareholding of 48% in ZIOC. "The acquisition is value accretive to shareholders and increases effective equity ownership of the project by existing shareholders, enhancing their look-through ownership of the project and securing control of the project without paying any premium for such interest," says Chair Clifford Elphick. Glencore Projects is a subsidiary of Swiss-based miner Glencore PLC.

----------

AIM - LOSERS

----------

Alliance Pharma PLC, down 30% at 42.46p, 12-month range 41.28p-122p. The distributor of consumer healthcare brands and prescription medicines says some larger orders in the fourth quarter of 2022 will not materialise. This is due to a slower-than-expected recovery in the business-to-business market, as well as a hit to sales from "a one-off destocking effect". It now expects annual revenue to be at least GBP170 million, with underlying pretax profit of at least GBP30 million. This is compared with 2021's revenue of GBP163.2 million and underlying pretax profit of GBP42.2 million. CEO Peter Butterfield will take time off from the business "for personal reasons", and return in January. Chief Financial Officer Andrew Franklin will assume his responsibilities in the meantime.

----------

Applied Graphene Materials PLC, down 39% at 3p, 12-month range 3p-28.5p. The graphene developer begins strategic review in light of its "funding position and...the unfavourable conditions in small-cap equity markets". The options pursued may include raising funds from a specialist debt provider or strategic investor, selling its trade and assets, or selling shares in its main operating subsidiary. It also decides to begin statutory redundancy consultations with its employees, to protect its financial position in case the review does not reach "a satisfactory conclusion".

----------

By Elizabeth Winter; elizabethwinter@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
17 Jun 2015 17:11

DIRECTOR DEALINGS: Alliance Pharma Non-Executive Director Buys Shares

Read more
27 May 2015 08:34

BROKER RATINGS SUMMARY: Brewin Dolphin Cut To Hold By Peel Hunt, Numis

Read more
27 May 2015 08:01

Alliance Pharma Trading Satisfactory On Solid Brand Performances

Read more
27 May 2015 07:23

LONDON MORNING BRIEFING: Imperial Tobacco, IAG Lead As Deals Approved

Read more
27 Mar 2015 09:34

BROKER RATINGS SUMMARY: Liberum Cuts Wolseley To Hold From Buy

Read more
25 Mar 2015 10:12

Alliance Pharma Posts Fall In Profit On Lower Revenue, Ups Dividend

Read more
25 Mar 2015 09:38

BROKER RATINGS SUMMARY: Investec Downgrades Barclays To Hold From Buy

Read more
17 Feb 2015 08:00

Alliance Pharma Finance Director Richard Wright To Step Down

Read more
2 Feb 2015 12:23

Alliance Pharma Acquires MacuVision For Initial GBP5.5 Million

Read more
20 Jan 2015 14:23

Tuesday tips round-up: Greene King, Alliance Pharma

Pub operator Greene King has seen a slowdown in its sales for the fiscal year-to-date, but its recent purchase of rival Spirit Pub Company will pay off. In the 36 weeks since the start of the financial year like-for-like sales were ahead by 0.6%, a mediocre result, even if it was partially due to to

Read more
19 Jan 2015 09:51

Alliance Pharma Says 2014 Pretax Profit To Meet Market Expectations

Read more
24 Sep 2014 09:15

Wednesday broker round-up UPDATE

Aggreko: Morgan Stanley ups target price from 1350p to 1375p, while leaving its underweight rating unaltered. Alliance Pharma: Canaccord Genuity lowers target price from 35p to 33p reiterating its hold recommendation. Close Brothers Group: UBS moves target price from 1420p to 1430p and keeps a neut

Read more
11 Sep 2014 08:35

UK BROKER RATINGS: Credit Suisse Upgrades TUI Travel To Outperform

Read more
10 Sep 2014 10:04

Alliance Pharma To Meet Annual Targets As Interim Profit Declines

Read more
10 Sep 2014 05:21

UK Earnings, Trading Statements Calendar - Week Ahead

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.